LIGAND PHARMACEUTICALS INC ($LGND)
Filing Information
| Accession Number | 0002001011-26-000115 |
|---|---|
| Form Type | 4 |
| Filing Date | Aug 14, 2026 |
| Document | View SEC Filing |
Transactions
11
Total Shares
94,923
Total Value
$11,041,802.88
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Common Stock | โ | Aug 12, 2026 | Exercise/Conversion | 16,179 | $52.84 | $854,898.36 | 43,875 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Aug 12, 2026 | Exercise/Conversion | 2,074 | $70.04 | $145,262.96 | 45,949 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Aug 12, 2026 | Exercise/Conversion | 2,869 | $55.75 | $159,946.75 | 48,818 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Aug 12, 2026 | Exercise/Conversion | 7,171 | $57.22 | $410,324.62 | 55,989 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Aug 12, 2026 | Exercise/Conversion | 3,348 | $68.74 | $230,141.52 | 59,337 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Aug 12, 2026 | Sale | 31,641 | $292.06 | $9,241,228.66 | 27,696 | Direct | โ | View Details | |
Chief Financial Officer | Employee Stock Option (right to buy) | Derivative | Aug 12, 2026 | Exercise/Conversion | 2,869 | $0.00 | $0.00 | 0 | Direct | โ | View Details | |
Chief Financial Officer | Employee Stock Option (right to buy) | Derivative | Aug 12, 2026 | Exercise/Conversion | 7,171 | $0.00 | $0.00 | 0 | Direct | โ | View Details | |
Chief Financial Officer | Non-Qualified Stock Option (right to buy) | Derivative | Aug 12, 2026 | Exercise/Conversion | 16,179 | $0.00 | $0.00 | 0 | Direct | โ | View Details | |
Chief Financial Officer | Non-Qualified Stock Option (right to buy) | Derivative | Aug 12, 2026 | Exercise/Conversion | 3,348 | $0.00 | $0.00 | 0 | Direct | โ | View Details | |
Chief Financial Officer | Non-Qualified Stock Option (right to buy) | Derivative | Aug 12, 2026 | Exercise/Conversion | 2,074 | $0.00 | $0.00 | 0 | Direct | โ | View Details |